Publishing of Orion Corporation's Interim Report for January-September 2014 on 21 October 2014

ORION CORPORATION     STOCK EXCHANGE RELEASE   8 OCTOBER 2014 at 9:00 a.m. EEST


Publishing of Orion Corporation's Interim Report for January-September 2014 on
21 October 2014


Orion will publish its Interim Report January-September 2014 on Tuesday, 21
October 2014 approximately at 12:00 Finnish time (EEST). The release and related
presentation material in Finnish and in English will be available on the Group's
homepage at www.orion.fi/en/Orion-group/investors promptly after the publishing.

News conference for analysts and media on Tuesday 21 October 2014 at 13:30 EEST

A news conference for analysts and media will be held on Tuesday 21 October
2014 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki.
President and CEO Timo Lappalainen will give a brief presentation in English on
the financial review.

Live webcast and conference call

The event can be followed live as a webcast accessible at
http://qsb.webcast.fi/o/orion/orion_2014_1021_q3

Questions can be asked also through conference call lines after the result
presentation.

The conference call ID is 948474 and the phone numbers to participate the
conference are:

when calling from the United States +1 334 323 6203
when calling from other countries +44 (0)20 7162 0125

News conference recordings

A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent period

The silent period preceding the publication is ongoing and continues until the
disclosure.


Orion Corporation



 Timo Lappalainen  Jari Karlson
 President and CEO CFO



Publisher:
Orion Corporation
www.orion.fi/en


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1, 007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1861438]